TG Therapeutics (TGTX) AI Stock Analysis

• Market Cap: $5.30B
• Dividend Yield: N/A
• Average Volume (3M): 2.03M
• Price to Earnings (P/E): 12.0
• Beta (1Y): 0.63
• Revenue Growth: 100.88%
• EPS Growth: N/A
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.43
• Shares Outstanding: 158,759,450
• 10 Day Avg. Volume: 1,972,180
• 30 Day Avg. Volume: 2,027,067
• PEG Ratio: 2.36
• Price to Book (P/B): 19.67
• Price to Sales (P/S): 13.29
• P/FCF Ratio: -107.84
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 13.08
• Enterprise Value/Gross Profit: 15.04
• Enterprise Value/Ebitda: 60.77
• 1Y Price Target: $45.00
• Price Target Upside: 34.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.75
• Revenue Forecast (FY): $606.01M

• Rating: 65 Neutral
• Price Target: $37.00 ▲(10.75% Upside)

TG Therapeutics' strong earnings call and valuation are significant positives, reflecting confidence in future growth and an undervalued stock. However, technical indicators suggest bearish momentum, and financial performance shows risks in cash flow management and debt reliance.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product adoption and market expansion, enhancing long-term financial stability.

Clinical Developments

Rapid enrollment in clinical trials suggests robust demand and potential for future product approvals, strengthening competitive position.

Market Expansion

Expanding market presence with new prescribers boosts revenue potential and solidifies the company's position in the MS treatment market.

Negative Factors

Cash Flow Challenges

Negative cash flows indicate potential liquidity issues, which could hinder investment in R&D and long-term growth initiatives.

Increased Operating Expenses

Rising operating expenses may pressure margins and profitability, impacting the company's ability to sustain long-term growth.

Limited Ex-U.S. Sales

Limited international sales growth restricts global market potential, potentially capping future revenue streams and diversification.

TG Therapeutics Business Overview & Revenue Model

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of B-cell malignancies and autoimmune diseases. The company operates primarily in the oncology and immunology sectors, with core products including its proprietary drug candidates, such as ublituximab, a next-generation anti-CD20 monoclonal antibody, and other therapies aimed at targeting specific pathways involved in these diseases.

How the Company Makes Money

TG Therapeutics generates revenue primarily through the sale of its therapeutics once they are approved by regulatory agencies and brought to market. The company also engages in partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of products developed through these partnerships. Additionally, TG Therapeutics may receive funding from grants or government programs aimed at supporting the development of innovative therapies. As the company progresses in clinical trials and gains regulatory approvals, its revenue potential increases significantly through market access and sales of its product portfolio.

TG Therapeutics Financial Statement Overview

Summary

TG Therapeutics shows strong revenue growth and improving profitability, with a significant increase in net profit margins. However, challenges in cash flow management and reliance on debt financing pose risks.

Income Statement

TG Therapeutics has shown impressive revenue growth, particularly in the TTM period with a 17.52% increase. The company maintains strong gross profit margins above 86%, indicating efficient cost management. Net profit margins have improved significantly, reaching 13.31% in the TTM, reflecting enhanced profitability. However, the company has a history of negative margins, which poses a risk if growth slows.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.92 in the TTM, indicating manageable leverage. Return on equity has improved to 26.05%, showcasing effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing, which could be risky in volatile markets.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in the TTM. The free cash flow to net income ratio is slightly above 1, indicating that cash flow generation is not yet robust. The negative growth in free cash flow highlights the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	454.07M	329.00M	233.66M	2.79M	6.69M	152.00K
Gross Profit	394.85M	290.52M	219.11M	2.52M	5.90M	152.00K
EBITDA	97.72M	49.90M	26.10M	-213.11M	-341.97M	-272.68M
Net Income	60.46M	23.38M	12.67M	-223.81M	-348.10M	-279.38M
Balance Sheet
Total Assets	702.61M	577.69M	329.59M	193.57M	379.63M	625.64M
Cash, Cash Equivalents and Short-Term Investments	251.87M	311.00M	217.51M	161.68M	314.76M	605.43M
Total Debt	253.72M	253.72M	110.80M	83.06M	79.05M	41.98M
Total Liabilities	426.18M	355.33M	169.09M	134.99M	142.48M	106.29M
Stockholders Equity	276.43M	222.36M	160.50M	58.59M	237.15M	519.35M
Cash Flow
Free Cash Flow	-59.24M	-40.56M	-31.41M	-176.18M	-296.04M	-214.86M
Operating Cash Flow	-59.13M	-40.52M	-31.41M	-176.17M	-295.63M	-214.51M
Investing Cash Flow	-10.47M	-1.04M	-50.65M	-20.01M	-332.00K	-24.51M
Financing Cash Flow	115.84M	128.53M	72.70M	-391.00K	41.42M	679.83M

TG Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.41
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 33.41 is above the 20-day moving average (MA) of 32.16, below the 50-day MA of 33.83, and below the 200-day MA of 34.91, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 56.11 is Neutral, neither overbought nor oversold. The STOCH value of 84.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.

TG Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	65 Neutral	$5.30B	12.03	111.96%	―	100.88%	―
JAZZ	63 Neutral	$10.75B	―	-9.06%	―	4.14%	-179.96%
IONS	58 Neutral	$13.40B	―	-39.99%	―	20.39%	34.00%
AXSM	55 Neutral	$7.61B	―	-275.50%	―	65.83%	28.50%
RYTM	52 Neutral	$7.17B	―	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NUVL	43 Neutral	$7.93B	―	-38.79%	―	―	-52.84%

TG Therapeutics Corporate Events

TG Therapeutics Earnings Call: Strong Growth and Positive Outlook

TG Therapeutics recently held an earnings call that conveyed a predominantly positive sentiment, underscored by robust financial performance and promising clinical developments. Despite some challenges, such as increased operating expenses and limited international sales growth, the highlights of the call significantly outweighed the lowlights, reflecting a strong quarter for the company.

TG Therapeutics Reports Strong Q3 2025 Results

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, with a particular emphasis on therapies for multiple sclerosis. In its latest earnings report, TG Therapeutics announced a strong third quarter for 2025, with total revenue reaching $161.7 million, driven primarily by the success of its product BRIUMVI in the U.S. market. The company has raised its full-year revenue guidance to $600 million, reflecting continued strong demand for BRIUMVI. Key financial highlights include a significant increase in net income to $390.9 million for the quarter, largely due to a non-recurring income tax benefit. The company also reported substantial growth in product revenue, with BRIUMVI U.S. net revenue experiencing an 84% increase compared to the same period in 2024. Additionally, TG Therapeutics has expanded its commercialization efforts internationally and achieved several pipeline development milestones. Looking ahead, TG Therapeutics remains focused on expanding patient awareness, advancing clinical trials, and driving long-term shareholder value, as indicated by the authorization of an additional $100 million share repurchase program.

TG Therapeutics’ New Study on Ublituximab: A Potential Game-Changer for Pediatric MS Treatment

The clinical study titled ‘Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)’ aims to assess the pharmacokinetics and pharmacodynamics of ublituximab in children aged 10 to under 18 with relapsing multiple sclerosis. The study also seeks to compare the efficacy of ublituximab with fingolimod, a current treatment option, and evaluate its long-term safety and efficacy.

TG Therapeutics’ Phase 3 Study: A New Approach to Multiple Sclerosis Treatment

Study Overview: TG Therapeutics is conducting a Phase 3 study titled A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab Versus Intravenous Ublituximab in Patients With Multiple Sclerosis. The study aims to compare the pharmacokinetics of subcutaneous versus intravenous administration of ublituximab in patients with relapsing multiple sclerosis (RMS), a significant endeavor to enhance treatment options for this condition.

TG Therapeutics’ Ublituximab Study: A Potential Game-Changer for RMS Treatment?

The recent clinical study update from TG Therapeutics focuses on evaluating the safety, efficacy, and pharmacokinetics of a modified regimen of ublituximab in patients with Relapsing Multiple Sclerosis (RMS). Officially titled ‘Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE)’, the study aims to measure the impact of this treatment on T1 Gadolinium-enhancing lesions, a key indicator of disease activity in RMS.

TG Therapeutics’ BRIUMVI® Study: Evaluating Safety in Pregnancy

Study Overview: TG Therapeutics is conducting a study titled BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®. The study aims to evaluate the prevalence of major congenital malformations (MCM) in pregnant participants with Multiple Sclerosis (MS) who are exposed to BRIUMVI® compared to those who are not. This research is significant as it seeks to provide crucial insights into the safety of BRIUMVI® during pregnancy.

TG Therapeutics’ BRIUMVI® Study: Real-World Insights for RMS Treatment

Study Overview: TG Therapeutics is conducting a study titled ‘REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)’ to assess the safety, effectiveness, and treatment experience of BRIUMVI® (ublituximab-xiiy) in patients with Relapsing Multiple Sclerosis (RMS). This study is significant as it aims to provide real-world insights into the drug’s performance outside of controlled clinical trials.

TG Therapeutics’ BRIUMVI™ Breast Milk Study: Key Insights for Investors

Study Overview: TG Therapeutics is conducting a post-marketing study titled ‘A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk’ (PROVIDE). The study aims to assess the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who are receiving the drug for the treatment of relapsing forms of multiple sclerosis (RMS). This research is significant as it addresses safety concerns for breastfeeding mothers undergoing treatment.

TG Therapeutics’ Promising Phase 1 Study on Azer-cel for Autoimmune Disorders

Study Overview: TG Therapeutics is conducting a Phase 1 study titled ‘A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders.’ The primary goal is to determine the recommended phase 2 dose of Azercabtagene zapreleucel (azer-cel), highlighting its potential significance in treating B-cell mediated autoimmune disorders.